Information  X 
Enter a valid email address

Henderson Morley PLC (HML)

  Print      Mail a friend

Wednesday 28 April, 2010

Henderson Morley PLC

Further re Grant Application

RNS Number : 9394K
Henderson Morley PLC
28 April 2010

28 April 2010  










The Board of Henderson Morley plc ("Henderson Morley"), the AIM quoted biotechnology company, announces that, following its application for Grant Funding from the Queensland Government funded Research Industry Partnership Programme ("RIPP") as announced on 5 November 2009, it has been notified by the Queensland Institute of Medical Research ("QIMR") that the application has been unsuccessful, even though it was short listed.


The Cytomegalovirus Vaccine funding was not granted  due to a shortage of funds within RIPP despite having been recommended to the Minister of Health.


Commenting, Andrew Knight, Henderson Morley's Executive Chairman, said "We continue to make applications for Grant funding both in the UK and Overseas and whilst we are disappointed not to have been successful on this occasion, we remain optimistic that we will receive Grant Funding in the future."











HENDERSON MORLEY PLC                                                          0121 442 4600

Andrew Knight, Chairman                                              


BISHOPSGATECOMMUNICATIONS LTD                                        0207 562 3350

Maxine Barnes

Gemma O'Hara


BREWIN DOLPHIN INVESTMENT BANKING                                   0113 241 0126

Neil Baldwin


RIVINGTON STREET CORPORATE FINANCE                                 0207 562 3380

Leo Godsall


Further information on Henderson Morley plc can be accessed through the Company's website at





This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t